Abstract

The tubulin molecule is a heterodimer composed of two polypeptide chains, designated alpha and beta; both alpha and beta exist in numerous isotypic forms, which differ in their assembly and drug binding properties. 2-(4-Fluorophenyl)-1-(2-chloro-3, 5-dimethoxyphenyl)-3-methyl-6-phenyl-4(1H)-pyridinone (IKP-104) is an antimitotic compound which inhibits polymerization and induces depolymerization of microtubules [Mizuhashi, F., et al. (1992) Jpn. J. Cancer Res. 83, 211]. Since the previous work was undertaken with isotypically unfractionated tubulin, we have investigated the interactions of IKP-104 with the isotypically purified tubulin dimers (alpha beta(II), alpha beta(III), and alpha beta(IV)). We find that IKP-104 binds to alpha beta(II) and alpha beta(III) at two classes of binding sites. However, affinities for each class of site are much weaker for alpha beta(III) than for alpha beta(II). Interestingly, the low-affinity site on alpha beta(IV) was not detectable. Its high-affinity site was weaker than those of either alpha beta(II) or alpha beta(III). In a pattern consistent with these results, IKP-104 inhibited assembly better with alpha beta(II) than with the other two dimers. Higher concentrations of IKP-104 induced formation of spiral aggregates from alpha beta(II) and alpha beta(III) but not from alpha beta(IV). Our results suggest that the interaction of IKP-104 with tubulin isotypes is very complex: alpha beta(II) and alpha beta(III) differ quantitatively in their interaction with IKP-104, and alpha beta(IV)'s interaction differs both quantitatively and qualitatively from those of the other two dimers.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.